Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. decreased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 25.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 559,835 shares of the specialty pharmaceutical company’s stock after selling 191,708 shares during the quarter. Victory Capital Management Inc. owned 0.98% of Supernus Pharmaceuticals worth $26,755,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in Supernus Pharmaceuticals by 8.8% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,375 shares of the specialty pharmaceutical company’s stock valued at $453,000 after purchasing an additional 1,161 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH raised its stake in shares of Supernus Pharmaceuticals by 30.4% during the 2nd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 85,534 shares of the specialty pharmaceutical company’s stock worth $2,696,000 after buying an additional 19,949 shares during the last quarter. Ruffer LLP acquired a new position in shares of Supernus Pharmaceuticals during the 3rd quarter worth $2,647,000. Systematic Financial Management LP boosted its position in shares of Supernus Pharmaceuticals by 47.5% in the 2nd quarter. Systematic Financial Management LP now owns 245,545 shares of the specialty pharmaceutical company’s stock worth $7,740,000 after buying an additional 79,041 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at about $1,301,000.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on SUPN. Stifel Nicolaus raised their target price on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a report on Friday, December 19th. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, January 29th. Finally, Craig Hallum set a $65.00 target price on Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $62.17.

Insider Activity

In other Supernus Pharmaceuticals news, Director Georges Gemayel sold 8,787 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Friday, March 6th. The shares were sold at an average price of $53.00, for a total value of $465,711.00. Following the completion of the sale, the director directly owned 27,277 shares of the company’s stock, valued at approximately $1,445,681. The trade was a 24.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Frank Mottola sold 20,000 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $50.41, for a total value of $1,008,200.00. Following the completion of the transaction, the senior vice president owned 15,496 shares of the company’s stock, valued at $781,153.36. This trade represents a 56.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 43,972 shares of company stock worth $2,270,833 in the last three months. 8.80% of the stock is owned by insiders.

Supernus Pharmaceuticals Trading Up 0.6%

NASDAQ:SUPN opened at $54.17 on Tuesday. The firm has a market cap of $3.12 billion, a price-to-earnings ratio of -79.66, a price-to-earnings-growth ratio of 1.67 and a beta of 0.70. The company’s 50-day moving average is $51.05 and its two-hundred day moving average is $48.90. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $59.68.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.